Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.69 |
| ▸ | CA12 | O43570 | 15/20 | 0.57 |
| ▸ | CA9 | Q16790 | 15/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 5/20 | 0.50 |
| ▸ | CA2 | P00918 | 5/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23928526 | 0.86 | PTGS2 (0.55) | PTGS2CA12CA9MEN1KMT2A | |
| SCHEMBL23928479 | 0.85 | KMT2A (0.70) | PTGS2MEN1KMT2ANLRP3 | |
| SCHEMBL12670646 | 0.85 | PTGS2 (0.67) | PTGS2CA12CA9MEN1KMT2A | |
| SCHEMBL23928554 | 0.83 | CA12 (0.72) | CA12CA9MEN1KMT2ACA1 | |
| SCHEMBL23928615 | 0.83 | PTGS2 (0.51) | PTGS2CA12CA9MEN1KMT2A | |
| SCHEMBL9048935 | 0.82 | PTGS2 (0.78) | PTGS2CA12CA9MEN1KMT2A | |
| SCHEMBL23928524 | 0.82 | PTGS2 (0.78) | PTGS2CA12CA9MEN1KMT2A | |
| SCHEMBL23928490 | 0.81 | PTGS2 (0.77) | PTGS2CA12CA9MEN1KMT2A | |
| SCHEMBL23928566 | 0.80 | PTGS2 (0.69) | PTGS2CA12CA9MEN1KMT2A | |
| SCHEMBL23928584 | 0.80 | PTGS2 (0.76) | PTGS2CA12CA9MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548875-B2 | Inhibitor compounds for male contraception | UNIVERSITY OF WASHINGTON (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210332030-A1 | INHIBITOR COMPOUNDS FOR MALE CONTRACEPTION | UNIVERSITY OF WASHINGTON (US) | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210332030-A1 | INHIBITOR COMPOUNDS FOR MALE CONTRACEPTION | ALDH1A1, ALDH3A1, ALDH16A1 | PTGS2 908/4885CA12 4702/4885CA9 4751/4885 |
| US-11548875-B2 | Inhibitor compounds for male contraception | ALDH1A1, ALDH3A1, ALDH16A1 | PTGS2 908/4885CA12 4702/4885CA9 4751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.